Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

The Lancet Oncology
Wenfeng FangLi Zhang

Abstract

Platinum-based doublet chemotherapy regimens, preferentially gemcitabine plus cisplatin, are generally considered the first-line standard of care for patients with recurrent or metastatic nasopharyngeal carcinoma. However, no consensus has been reached regarding treatment following progression after first-line therapy. Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody. We present safety and preliminary antitumour activity of camrelizumab alone as second-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma and combined with gemcitabine and cisplatin as first-line therapy in this patient population. We report the results from two single-arm, phase 1 trials. Both trials included patients aged 18-70 years with histologically or cytologically confirmed nasopharyngeal carcinoma and confirmed metastatic disease or locoreginal recurrence, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients who received at least one previous line of treatment were enrolled at five academic hospitals in China into the dose-escalation and expansion trial to receive camrelizumab monotherapy intravenously at escalating doses of 1 mg/kg, 3 mg/kg, and 10 mg/kg, and a brid...Continue Reading

Citations

Dec 6, 2018·MAbs·Hélène Kaplon, Janice M Reichert
May 1, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jing NieWeidong Han
Jul 18, 2019·Drugs·Anthony Markham, Susan J Keam
Jul 31, 2019·Expert Opinion on Biological Therapy·James Ch ChowWilliam Cs Cho
Jun 1, 2019·The New England Journal of Medicine·Yuan ZhangJun Ma
Jan 18, 2020·International Journal of Cancer. Journal International Du Cancer·Liam MastersonMatt Lechner
Mar 20, 2020·American Society of Clinical Oncology Educational Book·Brigette B Y MaJun Ma
Apr 7, 2020·Expert Opinion on Therapeutic Targets·Valentin BalochePierre Busson
Mar 17, 2020·Current Opinion in Oncology·Edwin Pun HuiAnthony T C Chan
Aug 9, 2020·Expert Review of Gastroenterology & Hepatology·Zhongguang ChenKelly Koral
Mar 27, 2019·Journal of the National Cancer Institute·Quynh Thu LeShakun Malik
Jun 13, 2020·Frontiers in Pharmacology·Jian-Ye ZhangLi-Wu Fu
Oct 28, 2019·Journal of Hematology & Oncology·Xiao-Dong Zhu, Hui-Chuan Sun
May 26, 2020·Cancer Chemotherapy and Pharmacology·Songbin GuoZhenfeng Zhang
May 22, 2019·The British Journal of Radiology·Liang PengJun Ma
Feb 29, 2020·World Journal of Clinical Cases·Qing Yu, Wen-Xia Wang
Apr 5, 2020·Journal of Hematology & Oncology·Chongxian PanLei Zheng
Jun 10, 2020·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·J BoustaniP Blanchard
Apr 8, 2020·Drug Design, Development and Therapy·Jason D LickliterTarek Meniawy
Jul 3, 2019·The British Journal of Radiology·Xue-Song SunHai-Qiang Mai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.